Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.43 USD
+0.07 (20.78%)
Updated May 16, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
Dare Bioscience, Inc. [DARE]
Reports for Purchase
Showing records 21 - 40 ( 213 total )
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b Topline Data Meaningful, Full Data Evaluation for Next Steps
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Xaciato Is Priced to Move as Launch Looks Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Daré Bioscience Sets Expectations For 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Focus on Imminent Sildenafil Cream Phase 2 Data in FSAD
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Focus on Phase 2b RESPOND Trial Data in FSAD, Ovaprene Phase 3 Initiation
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Daré Announces the Start - P1 Study for Primary Dysmenorrhea
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Focus on Advancing Innovative Drugs for Women''s Health - Resume Buy, $5 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Daré Announces New Development Program PDM1 for Primary Dysmenorrhea
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare Keeps the Early Pipeline Momentum Going; Reiterate Buy; Raise PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reports the Quarter - $40M in Cash Lots of Catalysts
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Daré Bioscience: Screening Begins for FSAD
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare''s Pipeline Continues to Advance; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Daré Bioscience announces results from the DARE-HRT1 Phase 1 / 2 Study
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J